Open AccessAnaplastic Large‐Cell Lymphoma, T‐/Null‐Cell Type
Author(s) -
Jacobsen Eric
Publication year - 2006
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.11-7-831
Subject(s) - anaplastic large cell lymphoma , medicine , lymphoma , confusion , disease , transplantation , t cell lymphoma , brentuximab vedotin , oncology , cancer research , cd30 , psychology , psychoanalysis
L earning O bjectives After completing this course, the reader will be able to: Identify areas of diagnostic confusion in anaplastic large‐cell lymphoma (ALCL). Describe risk stratification in ALCL. Discuss therapeutic options in ALCL.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com Anaplastic large‐cell lymphoma, T‐/null‐cell type (ALCL), is a rare disease that has only been well characterized for two decades. Despite this, the biology of ALCL is better understood than that of many other more common variants of lymphoma. This review focuses on the pathophysiology, clinical presentation, and therapy of ALCL, including stem cell transplantation. In particular, the text emphasizes how novel prognostic features and the evolving understanding of the biology of this disease will influence treatment selection and drug development.